On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Vivint Solar, Inc. (NYSE:VSLR), Continental Resources, Inc. (NYSE:CLR), Juno Therapeutics Inc. (NASDAQ:JUNO)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), with shares declined -4.95%, closed at $9.02.
Vivint Solar, Inc. (NYSE:VSLR), with shares dropped -4.95%, settled at $12.29.
Continental Resources, Inc. (NYSE:CLR), with shares dipped -4.89%, and closed at $39.06.
Juno Therapeutics Inc. (NASDAQ:JUNO), plummeted -4.63%, and closed at $58.68.
Latest NEWS regarding these Stocks are depicted underneath:
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Last Month, on February 18, BioCryst Pharmaceuticals, Inc. (BCRX), declared financial results for the fourth quarter and full year ended December 31, 2014.
Fourth Quarter Financial Results:
For the three months ended December 31, 2014, total proceeds reduced to $5.4 million from $10.6 million in the fourth quarter of 2013. The decrease in proceeds resulted primarily from the June 2014 expiration and related completion of development activities under the Biomedical Advanced Research and Development Authority/Health and Human Services (BARDA/HHS) peramivir development contract.
Research and Development (R&D) expenses for the fourth quarter of 2014 raised to $18.5 million from $15.5 million in the fourth quarter of 2013. The raise in 2014 R&D expense, as contrast to the fourth quarter of 2013, resulted from higher development costs associated with the hereditary angioedema (HAE) and BCX4430 programs, which were partially offset by a decrease in peramivir development expenses associated with the completion of the BARDA/HHS peramivir contract.
General and administrative (G&A) expenses for the fourth quarter of 2014 raised to $2.0 million contrast to $1.4 million in the fourth quarter of 2013, largely due to the vesting of performance-based stock options and RAPIVAB (peramivir injection) distribution expenses incurred in advance of approval.
Interest expense, which is related to non-recourse notes, was $1.3 million in the fourth quarter of 2014 and $1.2 million in the fourth quarter of 2013. Also, a $4.8 million mark-to-market gain on the Corporation’s foreign currency hedge was recognized in the fourth quarter of 2014, contrast to a $2.1 million mark-to-market gain in the fourth quarter of 2013. These gains result from periodic changes in the U.S. dollar/Japanese yen exchange rate and the related mark-to-market valuation of our underlying hedge arrangement.
The net loss for the fourth quarter of 2014 was $11.7 million, or $0.16 per share, contrast to a net loss of $5.4 million, or $0.09 per share, for the fourth quarter 2013.
BioCryst Pharmaceuticals, Inc., a biotechnology corporation, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates comprise peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE.
Vivint Solar, Inc. (NYSE:VSLR)
Vivint Solar, Inc. (VSLR), a leading provider of residential solar systems in the United States, declared that the corporation will present at the following forthcoming investor conference:
- Goldman Sachs Solar Leasing Symposium in New York, NY on Thursday, March 26, 2015.
Vivint Solar, Inc. provides distributed solar energy to residential customers in Arizona, California, Hawaii, Maryland, Massachusetts, New Jersey, New York, and Utah. It installs and owns solar energy systems through long-term customer contracts, such as power purchase contracts and solar energy system leases.
Continental Resources, Inc. (NYSE:CLR)
Last Month, on February 24, Continental Resources, Inc. (CLR), declared fourth quarter and full-year 2014 operating and financial results. Net revenue for the quarter ended December 31, 2014 was $114.0 million, or $0.31 per diluted share, contrast with net revenue of $132.8 million, or $0.36 per diluted share, for the fourth quarter of 2013. Not including items typically excluded from published analyst estimates, adjusted net revenue for the fourth quarter of 2014 was $420.8 million, or $1.14 per diluted share, an 84% raise over adjusted net revenue of $228.1 million, or $0.62 per diluted share, for the fourth quarter of 2013.
Net revenue for full-year 2014 was $977.3 million, or $2.64 per diluted share, contrast with net revenue of $764.2 million, or $2.07 per diluted share, for full-year 2013. Not including items typically excluded from published analyst estimates, adjusted net revenue for full-year 2014 was $1.27 billion, or $3.43 per diluted share, a 29% raise over adjusted net revenue of $986.1 million, or $2.67 per diluted share, for full-year 2013.
EBITDAX for the fourth quarter of 2014 was $1.19 billion, a 66% raise over EBITDAX of $712 million for the fourth quarter of 2013. Full-year 2014 EBITDAX was a record $3.78 billion, a 33% raise over EBITDAX of $2.84 billion for full-year 2013.
Fourth quarter 2014 net production totaled 17.8 million Boe, or 193,456 Boe per day, a sequential raise of 6% from third quarter 2014 and 34% higher than fourth quarter 2013. Total net production for the fourth quarter comprised of 136,972 barrels of oil per day (71% of production) and about 338.9 million cubic feet of natural gas per day (29% of production). Full-year 2014 production averaged 174,189 Boe per day, an raise of 28% contrast to full-year 2013. SCOOP volumes accounted for 20% of the total full-year 2014 volumes, up from 14% of the total full-year 2013 volumes.
Continental Resources, Inc. explores, develops, and produces crude oil and natural gas properties in the north, south, and east regions of the United States. The corporation sells its crude oil production to end users, in addition to midstream marketing companies or crude oil refining companies at the lease.
Juno Therapeutics Inc. (NASDAQ:JUNO)
Juno Therapeutics Inc. (JUNO), stated business highlights and financial results for the fourth quarter and year ended December 31, 2014.
- Positive momentum and progress on clinical trials continues.
- Strong year-end cash position of $474.1 million.
- 2015 cash burn guidance of $125 million to $150 million, not including cash inflows or outflows from business development activities and ongoing litigation.
“During the past year, we have made noteworthy progress in building a world class science and clinical organization. We have leveraged our CAR and TCR technology platform to continue to develop cellular therapeutics with the potential to meaningfully improve the lives of patients with cancer,” said Hans Bishop, Juno’s Chief Executive Officer. “Our successful rounds of private financing, together with our IPO, have offered us with the financial resources that we need to continue advancing our product candidates. Within the next 12 months, we expect to have 10 product candidates in clinical development directed at six different cancer-associated antigens.”
2015 Financial Guidance:
Juno anticipates to burn between $125 million and $150 million in cash in 2015, not including cash inflows or outflows from business development activities and ongoing litigation.
“Juno enters 2015 financially strong and prepared to support the initiation of clinical trials for multiple product candidates targeting an array of antigens, our planned Phase II trial of JCAR015, and other milestones,” said Steven M. Harr, M.D., Chief Financial Officer of Juno. “Our financial guidance for 2015 provides evidence of our commitment to patients and to investors to deliver on our business strategy, to spend prudently, and to invest in the innovation and development of therapies that re-engage the immune system to fight cancer.”
Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical corporation focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
